Daniel H. Follansbee
Mergers & Acquisitions
- Represented QIAGEN N.V. in the $260M acquisition of the digital pcr assets of Formulatrix, Inc.
- Represented QIAGEN N.V. in its $234M strategic partnership with NeuMoDx Molecular, Inc.
- Represented Dassault Systèmes in its $425M acquisition of IQMS, Inc.
- Represented Dassault Systèmes in its acquisition of No Magic, Incorporated
Venture Capital
- Represented Mitra RxDx (dba Mitra Biotech) in its $40M financing led by Northpond Ventures, and included Accel, Sequoia Capital, Sands Capital Ventures, and RA Capital Management
- Represented Endotronix, Inc. in its $40M Series D financing led by LSP, investing from its LSP Health Economics Fund 2, and included Aperture Venture Partners, BioVentures Investors, Lumira Ventures, OSF Ventures, Seroba Life Sciences, SV Health Investors, Wanxiang Healthcare Investments, and an unnamed corporate strategic investor
Case Study
Mintz represented Granahan Investment Management, a small cap equity investment boutique with $5.8 billion in assets under management, in the recently completed sale of a minority interest in GIM to Kudu Investment Management. GIM’s employees will continue to hold 75% of the equity in the firm.
Case Study
Mintz advised Seventh Generation, a maker of environmentally friendly household cleaning products, from its beginnings as a catalog company through its evolution into a leading “green” company. Mintz also represented the company in its sale to Unilever.
Case Study
Mintz was lead counsel to Beth Israel Deaconess Medical Center in the sale of BIDMC’s hospital-built electronic health records platform to Athenahealth. Mintz also helped negotiate an agreement for BIDMC’s physician network to use the multiuse Athena’s platform.